Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a genetically heterogeneous cancer that frequently exhibits aberrant kinase signaling. We investigated a treatment strategy combining sorafenib, a multikinase inhibitor with limited single-agent activity in AML, and cytarabine, a key component of AML chemo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hu, Shuiying, Niu, Hongmei, Inaba, Hiroto, Orwick, Shelley, Rose, Charles, Panetta, John C., Yang, Shengping, Pounds, Stanley, Fan, Yiping, Calabrese, Christopher, Rehg, Jerold E., Campana, Dario, Rubnitz, Jeffrey E., Baker, Sharyn D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2011
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3110171/
https://ncbi.nlm.nih.gov/pubmed/21487100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr107
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge